Author Correction: miR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR–p-PI3K/AKT-c-JUN (Nature Communications, (2016), 7, 1, (11309), 10.1038/ncomms11309);MiR-3188 regulates nasopharyngeal carcinoma proliferation and chemosensitivity through a FOXO1-modulated positive feedback loop with mTOR-p-PI3K/AKT-c-JUN

Nature Communications

Volumn 7, Issue , 2016, Pages

  Zhao, Mengyang ^a   Luo, Rongcheng ^a   Liu, Yiyi ^a   Gao, Linyuan ^a   Fu, Zhaojian ^a   Fu, Qiaofen ^a   Luo, Xiaojun ^a   Chen, Yiyu ^a   Deng, Xiaojie ^a   Liang, Zixi ^a   Li, Xin ^a   Cheng, Chao ^a   Liu, Zhen ^a,b   Fang, Weiyi ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b GUANGZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL; MAMMALIAN TARGET OF RAPAMYCIN; MICRORNA; MICRORNA 3188; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN C JUN; PROTEIN KINASE B; TRANSCRIPTION FACTOR FKHR; UNCLASSIFIED DRUG; FORKHEAD TRANSCRIPTION FACTOR; FOXO1 PROTEIN, HUMAN; MIRN3189 MICRORNA, HUMAN; MTOR PROTEIN, HUMAN; STRESS ACTIVATED PROTEIN KINASE; TARGET OF RAPAMYCIN KINASE;

CANCER; CELLS AND CELL COMPONENTS; CHEMOTHERAPY; ENZYME ACTIVITY; GENE EXPRESSION; GROWTH RATE; PROTEIN; RODENT; TUMOR;

ADULT; AGED; ANIMAL CELL; ARTICLE; CANCER RESISTANCE; CARCINOGENESIS; CELL GROWTH; CELL PROLIFERATION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR CLINICAL STUDY; MALE; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; POSITIVE FEEDBACK; PROTEIN EXPRESSION; SURVIVAL TIME; ANIMAL; CANCER STAGING; CANCER TRANSPLANTATION; CELL TRANSFORMATION; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; PATHOLOGY; PHYSIOLOGICAL FEEDBACK; PROGNOSIS; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TUMOR CELL LINE; VERY ELDERLY;

MUS;

ADULT; AGED; AGED, 80 AND OVER; ANIMALS; CELL LINE, TUMOR; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; FEEDBACK, PHYSIOLOGICAL; FEMALE; FORKHEAD BOX PROTEIN O1; FORKHEAD TRANSCRIPTION FACTORS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; JNK MITOGEN-ACTIVATED PROTEIN KINASES; MALE; MICE; MICRORNAS; MIDDLE AGED; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; NEOPLASM TRANSPLANTATION; PHOSPHATIDYLINOSITOL 3-KINASES; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; SURVIVAL ANALYSIS; TOR SERINE-THREONINE KINASES;

EID: 84964596802     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/s41467-021-22959-7     Document Type: Erratum

References (47)

1. Miska, E. A. How microRNAs control cell division, differentiation and death. Curr. Opin. Genet. Dev. 15, 563-568 (2005).
2. Lin, C. et al. miR-508 sustains phosphoinositide signalling and promotes aggressive phenotype of oesophageal squamous cell carcinoma. Nat. Commun. 5, 4620 (2014).
3. Jannot, G. & Simard, M. J. Tumour-related microRNAs functions in Caenorhabditis elegans. Oncogene 25, 6197-6201 (2006).
4. Meng, F. et al. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology 130, 2113-2129 (2006).
5. Sun, L. et al. MiR-200b and miR-15b regulate chemotherapy-induced epithelial-mesenchymal transition in human tongue cancer cells by targeting BMI1. Oncogene 31, 432-445 (2012).
6. Brennan, B. Nasopharyngeal Carcinoma. Orphanet. J. Rare Dis. 1, 23 (2006).
7. Chang, E. T. & Adami, H. O. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol. Biomarkers Prev. 15, 1765-1777 (2006).
8. Cai, L. M. et al. EBV-miR-BART7-3p promotes the EMT and metastasis of nasopharyngeal carcinoma cells by suppressing the tumor suppressor PTEN. Oncogene 34, 2156-2166 (2015).
9. Young, J. J. & Miller, R. W. Incidence of malignant tumors in U. S. children. J. Pediatr. 86, 254-258 (1975).
10. Cai, L. M. et al. Epstein-Barr virus-encoded microRNA BART1 induces tumour metastasis by regulating PTEN-dependent pathways in nasopharyngeal carcinoma. Nat. Commun. 6, 7353 (2015).
11. Zhen, Y. et al. Tumor suppressor PDCD4 modulates miR-184-mediated direct suppression of C-MYC and BCL2 blocking cell growth and survival in nasopharyngeal carcinoma. Cell Death Dis. 4, e872 (2013).
12. Brunet, A. et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96, 857-868 (1999).
13. Tang, E. D., Nunez, G., Barr, F. G. & Guan, K. L. Negative regulation of the forkhead transcription factor FKHR by Akt. J. Biol. Chem. 274, 16741-16746 (1999).
14. Grinius, L., Kessler, C., Schroeder, J. & Handwerger, S. Forkhead transcription factor FOXO1A is critical for induction of human decidualization. J. Endocrinol. 189, 179-187 (2006).
15. Zhou, L. et al. Mechanism and function of decreased FOXO1 in renal cell carcinoma. J. Surg. Oncol. 105, 841-847 (2012).
16. Xie, L. et al. FOXO1 is a tumor suppressor in classical Hodgkin lymphoma. Blood 119, 3503-3511 (2012).
17. Wu, Y. et al. Expression of FOXO1 is associated with GATA3 and Annexin-1 and predicts disease-free survival in breast cancer. Am. J. Cancer Res. 2, 104-115 (2012).
18. Bois, P. R. et al. FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J. Cell Biol. 170, 903-912 (2005).
19. Mei, Y. P. et al. Silencing of LMP1 induces cell cycle arrest and enhances chemosensitivity through inhibition of AKT signaling pathway in EBV-positive nasopharyngeal carcinoma cells. Cell Cycle 6, 1379-1385 (2007).
20. Yip, W. K., Leong, V. C., Abdullah, M. A., Yusoff, S. & Seow, H. F. Overexpression of phospho-Akt correlates with phosphorylation of EGF receptor, FKHR and BAD in nasopharyngeal carcinoma. Oncol. Rep. 19, 319-328 (2008).
21. Park, J. et al. The forkhead transcription factor FOXO1 mediates cisplatin resistance in gastric cancer cells by activating phosphoinositide 3-kinase/Akt pathway. Gastric Cancer 17, 423-430 (2014).
22. Parikh, A. et al. microRNA-181a has a critical role in ovarian cancer progression through the regulation of the epithelial-mesenchymal transition. Nat. Commun. 5, 2977 (2014).
23. Guo, S. L. et al. Akt-p53-miR-365-cyclin D1/cdc25A axis contributes to gastric tumorigenesis induced by PTEN deficiency. Nat. Commun. 4, 2544 (2013).
24. Santi, D. V., McHenry, C. S. & Sommer, H. Mechanism of interaction of thymidylate synthetase with 5-fluorodeoxyuridylate. Biochemistry 13, 471-481 (1974).
25. Haslehurst, A. M. et al. EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 12, 91 (2012).
26. Zhang, P. et al. Epithelial-mesenchymal transition is necessary for acquired resistance to cisplatin and increases the metastatic potential of nasopharyngeal carcinoma cells. Int. J. Mol. Med. 33, 151-159 (2014).
27. Siu, M. K. et al. Transforming growth factor-beta promotes prostate bone metastasis through induction of microRNA-96 and activation of the mTOR pathway. Oncogene 34, 4767-4776 (2015).
28. Robb, V. A., Karbowniczek, M., Klein-Szanto, A. J. & Henske, E. P. Activation of the mTOR signaling pathway in renal clear cell carcinoma. J. Urol. 177, 346-352 (2007).
29. Ghayad, S. E. et al. mTOR inhibition reverses acquired endocrine therapy resistance of breast cancer cells at the cell proliferation and gene-expression levels. Cancer Sci. 99, 1992-2003 (2008).
30. Huang, X. M. et al. Overproduction of cyclin D1 is dependent on activated mTORC1 signal in nasopharyngeal carcinoma: implication for therapy. Cancer Lett. 279, 47-56 (2009).
31. Chen, J. et al. Platelet-activating factor receptor-mediated PI3K/AKT activation contributes to the malignant development of esophageal squamous cell carcinoma. Oncogene 34, 5114-5127 (2015).
32. Yun, S. M. et al. PPP1R1B-STARD3 chimeric fusion transcript in human gastric cancer promotes tumorigenesis through activation of PI3K/AKT signaling. Oncogene 33, 5341-5347 (2014).
33. Fresno, V. J. et al. PI3K/Akt signalling pathway and cancer. Cancer Treat Rev. 30, 193-204 (2004).
34. Morgensztern, D. & McLeod, H. L. PI3K/Akt/mTOR pathway as a target for cancer therapy. Anticancer Drugs 16, 797-803 (2005).
35. Bjornsti, M. A. & Houghton, P. J. The TOR pathway: a target for cancer therapy. Nat. Rev. Cancer 4, 335-348 (2004).
36. OReilly, K. E. et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res. 66, 1500-1508 (2006).
37. Carracedo, A. et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer. J. Clin. Invest. 118, 3065-3074 (2008).
38. Zhang, H. et al. Loss of Tsc1/Tsc2 activates mTOR and disrupts PI3K-Akt signaling through downregulation of PDGFR. J. Clin. Invest. 112, 1223-1233 (2003).
39. Chakraborty, A., Diefenbacher, M. E., Mylona, A., Kassel, O. & Behrens, A. The E3 ubiquitin ligase Trim7 mediates c-Jun/AP-1 activation by Ras signalling. Nat. Commun. 6, 6782 (2015).
40. Lamb, R. F. et al. AP-1-mediated invasion requires increased expression of the hyaluronan receptor CD44. Mol. Cell Biol. 17, 963-976 (1997).
41. Yu, X. et al. Loss of connective tissue growth factor as an unfavorable prognosis factor activates miR-18b by PI3K/AKT/C-Jun and C-Myc and promotes cell growth in nasopharyngeal carcinoma. Cell Death Dis. 4, e634 (2013).
42. Zhang, L. et al. microRNA-141 is involved in a nasopharyngeal carcinomarelated genes network. Carcinogenesis 31, 559-566 (2010).
43. Liu, N. et al. MiR-29c suppresses invasion and metastasis by targeting TIAM1 in nasopharyngeal carcinoma. Cancer Lett. 329, 181-188 (2013).
44. Ebert, M. S. & Sharp, P. A. Roles for microRNAs in conferring robustness to biological processes. Cell 149, 515-524 (2012).
45. Que, T. et al. Decreased miRNA-637 is an unfavorable prognosis marker and promotes glioma cell growth, migration and invasion via direct targeting Akt1. Oncogene 34, 4952-4963 (2015).
46. Liu, C. G. et al. An oligonucleotide microchip for genome-wide microRNA profiling in human and mouse tissues. Proc. Natl Acad. Sci. USA 101, 9740-9744 (2004).
47. Ahmed, F. E. Microarray RNA transcriptional profiling: Part II. Analytical considerations and annotations. Exp. Rev. Mol. Diagn. 6, 736-750 (2006).